ArticleImmunity, inflammation and disease2025
Clonorchis sinensis Crude Antigen Suppresses Osteoclast Differentiation via Modulation of the NF-κB and MAPK Signaling Pathway.
Article in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MiR-21 promotes osteogenic transformation in ankylosing spondylitis fibroblasts and modulates bone metabolism in a murine arthritis model potentially involving the MAPK NF-κB pathway.Journal of orthopaedic surgery and research · 2026Article
- Clonorchis sinensis Crude Antigen Suppresses Osteoclast Differentiation via Modulation of the NF-κB and MAPK Signaling Pathway.Immunity, inflammation and disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundClonorchis sinensis crude antigen (CsCA) is recognized for its immunomodulatory capacity in host-pathogen interactions and immune-related pathologies, its direct impact on bone remodeling cells remains underexplored. Although prior studies demonstrate CsCA-mediated suppression of inflammatory bone formation in ankylosing spondylitis, the specific regulatory effects on osteoclastogenesis and associated molecular mechanisms remain elusive. This study aimed to investigate the impact of CsCA on osteoclast differentiation and its potential molecular mechanisms.
methodsThe cytotoxicity of CsCA on mouse bone marrow-derived macrophages (BMMs) was evaluated using the CCK-8 assay. At the established non-cytotoxic dose, the effects of CsCA on osteoclast morphology and activity were observed via TRAcP staining and F-actin ring formation assay. Expression of osteoclast differentiation-related genes and proteins was analyzed by combined RT-qPCR and Western Blot. RNA-seq was performed to identify CsCA-regulated signaling pathways during osteoclast differentiation, followed by validation of key pathway components through Western Blot and immunofluorescence.
resultsCsCA exhibited no significant cytotoxicity on BMMs at concentrations ≤ 40 μg/mL. TRAcP staining revealed a significant reduction in osteoclast numbers in CsCA-treated groups. F-actin ring formation assays demonstrated abnormal cytoskeletal structures. RT-PCR results showed significantly downregulated expression of osteoclast differentiation-related genes, including NFATc1, c-Fos, Acp5, CTSK and MMP-9. Western Blot confirmed reduced protein expression levels of NFATc1 and c-Fos. RNA-seq analysis combined with experimental validation by Western Blot and immunofluorescence confirmed that CsCA primarily inhibits osteoclast differentiation through the NF-κB and MAPK signaling pathways.
conclusionsCsCA inhibits the formation and function of osteoclasts by suppressing the expression of key genes involved in osteoclast differentiation through the inhibition of the NF-κB and MAPK signaling pathways. This study elucidates the mechanism by which CsCA regulates osteoclasts and suggests its translational potential in preventing and treating hyper-resorptive bone diseases such as osteoporosis and bone metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.